common glp 1 agonist America's Poison Centers GLP-1 receptor agonists and next-generation
Description
[DOI] [PubMed] [Google Scholar] 70
Im seeing real positive impact in my patients in clinic every day
10.1038/s44220-025-00390-x 18 de PaivaI
Tapering Protocol: To mitigate this, Iyengar suggested considering a dose taper over at least 20 weeks
Less common adverse effects were a temporary increase in alanine aminotransferase (ALT) levels, increased heart rate, and skin hyperesthesia [39]
Clinical trial data from the STEP program showed that semaglutide 2.4mg weekly produced average weight loss of 14.9% of body weight over 68 weeks, compared to tirzepatide at 15mg which achieved approximately 22.5% in the SURMOUNT trials
